DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 458-468

  van Jaarsveld, Marijn T M ^a   Wouters, Maikel D ^b   Boersma, Antonius W M ^a   Smid, Marcel ^a   van IJcken, Wilfred F J ^b   Mathijssen, Ron H J ^a   Hoeijmakers, Jan H J ^b   Martens, John W M ^a   van Laere, Steven ^c   Wiemer, Erik A C ^a   Pothof, Joris ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Oncology Centre of Antwerp   (Belgium)

Author keywords

Cancer; Chemotherapy; DNA damage response; MicroRNAs; Therapy resistance

Indexed keywords

CISPLATIN; DOXORUBICIN; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; MICRORNA 21; PACLITAXEL; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; BREAST CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CELL AGING; CELL COUNT; CELL CYCLE ARREST; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; EPITHELIUM CELL; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; STEM CELL; UPREGULATION; CELL CULTURE; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELLS, CULTURED; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84899488273     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.12.011     Document Type: Article

References (50)

1. Alexandre J., Hu Y., Lu W., Pelicano H., Huang P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res. 2007, 67:3512-3517.
2. Allen K.E., Weiss G.J. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol. Cancer Ther. 2010, 9:3126-3136.
3. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J.Clin. Oncol. 2008, 26:3785-3790.
4. Bartek J., Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr. Opin. Cell Biol. 2007, 19:238-245.
5. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
6. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Orntoft T., Lukas J., Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
7. Blower P.E., Chung J.H., Verducci J.S., Lin S., Park J.K., Dai Z., Liu C.G., Schmittgen T.D., Reinhold W.C., Croce C.M., Weinstein J.N., Sadee W. MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther. 2008, 7:1-9.
8. Bouwman P., Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer 2012, 12:587-598.
9. Bunnak J., Takigami M., Ito H., Shinozawa T. Gamma irradiation effects on cultured cells: investigated by the MTT method. J.Radiat. Res. 1994, 35:205-212.
10. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47:936-942.
11. Coppe J.P., Patil C.K., Rodier F., Sun Y., Munoz D.P., Goldstein J., Nelson P.S., Desprez P.Y., Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008, 6:2853-2868.
12. Dai Y., Xie C.H., Neis J.P., Fan C.Y., Vural E., Spring P.M. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck 2011, 33:786-791.
13. Danesi C.C., Bellagamba B.C., Dihl R.R., de Andrade H.H., Cunha K.S., Spano M.A., Reguly M.L., Lehmann M. Mutagenic evaluation of combined paclitaxel and cisplatin treatment in somatic cells of Drosophila melanogaster. Mutat. Res. 2010, 696:139-143.
14. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., Wicha M.S. Invitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17:1253-1270.
15. Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer. J.Pathol. 2011, 223:102-115.
16. Garzon R., Calin G.A., Croce C.M. MicroRNAs in cancer. Annu. Rev. Med. 2009, 60:167-179.
17. Giovannetti E., Erozenci A., Smit J., Danesi R., Peters G.J. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol. 2012, 81:103-122.
18. Giovannetti E., Funel N., Peters G.J., Del Chiaro M., Erozenci L.A., Vasile E., Leon L.G., Pollina L.E., Groen A., Falcone A., Danesi R., Campani D., Verheul H.M., Boggi U. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70:4528-4538.
19. Gordon R.R., Nelson P.S. Cellular senescence and cancer chemotherapy resistance. Drug Resist. Updat. 2012, 15:123-131.
20. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
21. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
22. Haenisch S., Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics 2012, 4:369-381.
23. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
24. Hoeijmakers J.H. DNA damage, aging, and cancer. N.Engl. J. Med. 2009, 361:1475-1485.
25. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2:277-288.
26. Li Y., Li W., Yang Y., Lu Y., He C., Hu G., Liu H., Chen J., He J., Yu H. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res. 2009, 1286:13-18.
27. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
28. Ma K., He Y., Zhang H., Fei Q., Niu D., Wang D., Ding X., Xu H., Chen X., Zhu J. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J.Biol. Chem. 2012, 287:5639-5649.
29. Meng F., Henson R., Lang M., Wehbe H., Maheshwari S., Mendell J.T., Jiang J., Schmittgen T.D., Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129.
30. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
31. Postel-Vinay S., Vanhecke E., Olaussen K.A., Lord C.J., Ashworth A., Soria J.C. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat. Rev. Clin. Oncol. 2012, 9:144-155.
32. Pothof J., Verkaik N.S., van I.W., Wiemer E.A., Ta V.T., van der Horst G.T., Jaspers N.G., van Gent D.C., Hoeijmakers J.H., Persengiev S.P. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. Embo J. 2009, 28:2090-2099.
33. Rademakers S., Volker M., Hoogstraten D., Nigg A.L., Mone M.J., Van Zeeland A.A., Hoeijmakers J.H., Houtsmuller A.B., Vermeulen W. Xeroderma pigmentosum group A protein loads as a separate factor onto DNA lesions. Mol. Cell Biol. 2003, 23:5755-5767.
34. Riaz M., van Jaarsveld M.T., Hollestelle A., Prager-van der Smissen W.J., Heine A.A., Boersma A.W., Liu J., Helmijr J., Ozturk B., Smid M., Wiemer E.A., Foekens J.A., Martens J.W. MicroRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res. 2013, 15:R33.
35. Rodier F., Munoz D.P., Teachenor R., Chu V., Le O., Bhaumik D., Coppe J.P., Campeau E., Beausejour C.M., Kim S.H., Davalos A.R., Campisi J. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J.Cell Sci. 2011, 124:68-81.
36. Sabin R.J., Anderson R.M. Cellular senescence - its role in cancer and the response to ionizing radiation. Genome Integr. 2011, 2:7.
37. Saeed A.I., Sharov V., White J., Li J., Liang W., Bhagabati N., Braisted J., Klapa M., Currier T., Thiagarajan M., Sturn A., Snuffin M., Rezantsev A., Popov D., Ryltsov A., Kostukovich E., Borisovsky I., Liu Z., Vinsavich A., Trush V., Quackenbush J. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34:374-378.
38. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., Wong K.K., Brandstetter K., Wittner B., Ramaswamy S., Classon M., Settleman J. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
39. Shi L., Chen J., Yang J., Pan T., Zhang S., Wang Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 2010, 1352:255-264.
40. Simone N.L., Soule B.P., Ly D., Saleh A.D., Savage J.E., Degraff W., Cook J., Harris C.C., Gius D., Mitchell J.B. Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS ONE 2009, 4:e6377.
41. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
42. Tseng R.C., Hsieh F.J., Shih C.M., Hsu H.S., Chen C.Y., Wang Y.C. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study. Cancer 2009, 115:2939-2948.
43. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U S A 2001, 98:5116-5121.
44. Van der Auwera I., Limame R., van Dam P., Vermeulen P.B., Dirix L.Y., Van Laere S.J. Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br. J. Cancer 2010, 103:532-541.
45. van Jaarsveld M.T., Helleman J., Boersma A.W., van Kuijk P.F., van Ijcken W.F., Despierre E., Vergote I., Mathijssen R.H., Berns E.M., Verweij J., Pothof J., Wiemer E.A. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013, 32:4284-4293.
46. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U S A 2006, 103:2257-2261.
47. Wiemer E.A.C. Role of MicroRNAs in anticancer drug resistance. MicroRNAs in Cancer Translational Research 2011, 449-483. Springer Verlag. W.C.S. Cho (Ed.).
48. Wouters M.D., van Gent D.C., Hoeijmakers J.H., Pothof J. MicroRNAs, the DNA damage response and cancer. Mutat. Res. 2011, 717:54-66.
49. Xia L., Zhang D., Du R., Pan Y., Zhao L., Sun S., Hong L., Liu J., Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123:372-379.
50. Zhang X., Wan G., Berger F.G., He X., Lu X. The ATM kinase induces microRNA biogenesis in the DNA damage response. Mol. Cell 2011, 41:371-383.